STOCK TITAN

Pharma-Bio Serv (PBSV) director records transfer of 42,504 shares to adult children

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

SPINDEL HOWARD reported disposition transactions in this Form 4 filing.

Pharma-Bio Serv, Inc. director Howard Spindel reported an estate-related restructuring of holdings in the company’s common stock. On 2026-06-09, 42,504 shares previously reported as indirectly owned through his spouse were transferred to the couple’s adult children at $0.00 per share. Following this transfer, Spindel reports 0 shares of common stock owned. He expressly disclaims beneficial ownership of the transferred shares, stating this report should not be deemed an admission that he is their beneficial owner for Section 16 or any other purpose.

Positive

  • None.

Negative

  • None.
Insider SPINDEL HOWARD
Role Director
Type Security Shares Price Value
Other Common Stock F1 42,504 $0.00 $0.00
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 0 shares (Indirect, By Spouse); Common Stock — 0 shares (Direct)
Footnotes (1)
  1. F1. Following the death of the reporting person's spouse, such shares were transferred to the reporting person's adult children. The reporting person disclaims beneficial ownership of these shares, and this report should not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
Shares transferred 42,504 shares Common stock transferred from indirect spousal ownership to adult children
Transaction price per share $0.00 Reported price for the 42,504-share transfer on 2026-06-09
Shares owned after transaction 0 shares Total Pharma-Bio Serv common stock reported following the transfer
Transaction date 2026-06-09 Date of the estate-related restructuring coded as transaction type J
beneficial ownership regulatory
"The reporting person disclaims <b>beneficial ownership</b> of these shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"beneficial owner of these shares for purposes of <b>Section 16</b>"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
indirect financial
"Shares were previously reported as <b>indirect</b> ownership "By Spouse""
reporting person regulatory
"Following the death of the <b>reporting person</b>'s spouse, such shares were transferred"
other acquisition or disposition regulatory
"Transaction code J indicates an <b>other acquisition or disposition</b>"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Pharma-Bio Serv (PBSV) director Howard Spindel report in this Form 4?

Howard Spindel reported an estate-related transfer of 42,504 shares of Pharma-Bio Serv common stock previously attributed to his late spouse. The shares moved to the couple’s adult children, and Spindel now reports 0 shares owned while explicitly disclaiming beneficial ownership of the transferred shares.

How many Pharma-Bio Serv (PBSV) shares were transferred and to whom?

A total of 42,504 common shares of Pharma-Bio Serv were transferred to the reporting person’s adult children. These shares had been reported as indirectly owned through his spouse, and the transfer followed the spouse’s death, with no price paid in the transaction.

Does Howard Spindel still own Pharma-Bio Serv (PBSV) shares after this transaction?

After the reported transaction, Howard Spindel reports owning 0 shares of Pharma-Bio Serv common stock, both directly and indirectly. The filing also states he disclaims beneficial ownership of the 42,504 shares transferred to his adult children, limiting any claim over those securities.

Was this Pharma-Bio Serv (PBSV) transaction a market sale or purchase?

No, it was not a market sale or purchase. The filing uses Form 4 code J, indicating an “other” type of disposition, with a reported price of $0.00 per share, reflecting an estate-related transfer of shares to the reporting person’s adult children.

Was the Pharma-Bio Serv (PBSV) transaction under a Rule 10b5-1 trading plan?

No. The Form 4’s Rule 10b5-1 checkbox is shown as not checked, and the footnote does not describe any pre-arranged trading plan. The transaction is characterized instead as a transfer following the death of the reporting person’s spouse.

What does “beneficial ownership” mean in this Pharma-Bio Serv (PBSV) filing?

In this context, “beneficial ownership” refers to having economic or voting power over shares. The director states he disclaims beneficial ownership of the 42,504 transferred shares, and the report should not be taken as admitting he is their beneficial owner under Section 16.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SPINDEL HOWARD

(Last)(First)(Middle)
7000 WEST PALMETTO PARK ROAD
SUITE 503

(Street)
BOCA RATON FLORIDA 33433

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Pharma-Bio Serv, Inc. [ PBSV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/09/2026J(1)42,504D$00IBy Spouse
Common Stock0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Following the death of the reporting person's spouse, such shares were transferred to the reporting person's adult children. The reporting person disclaims beneficial ownership of these shares, and this report should not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
/s/ Howard Spindel07/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)